Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7

Blood (2012) 120 (21): 1699.

https://doi.org/10.1182/blood.V120.21.1699.1699

Published: 2012

Journal Articles

Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia

Katharina Wagner, MD, Anna Both, Frederik Damm, MD, Felicitas Thol, MD, Gudrun Göhring, MD, Michael Heuser, MD, Oliver G. Ottmann, MD, Michael Lübbert, MD, Mohammed Wattad, MD, Lothar Kanz, MD, Günther Schlimok, MD, Aruna Raghavachar, MD, Walter Fiedler, MD, Hartmut Kirchner, MD, Wolfram Brugger, MD, Brigitte Schlegelberger, Gerhard Heil, MD, Arnold Ganser, Jürgen Krauter, Prof. Dr. med.

Blood (2012) 120 (21): 1381.

https://doi.org/10.1182/blood.V120.21.1381.1381

Published: 2012

Journal Articles

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Felicitas Thol, MD, Britta Kölking, Iris H.I.M. Hollink, MD, PhD, Frederik Damm, MD, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan, MD, PhD, Gesine Bug, Oliver G. Ottmann, MD, Katharina Wagner, MD, Michael A Morgan, PhD, Wolf-Karsten Hofmann, Gudrun Göhring, MD, Brigitte Schlegelberger, Jürgen Krauter, Prof. Dr. med., Arnold Ganser, Michael Heuser, MD

Blood (2012) 120 (21): 1402.

https://doi.org/10.1182/blood.V120.21.1402.1402

Published: 2012

Journal Articles

Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2012) 120 (21): 357.

https://doi.org/10.1182/blood.V120.21.357.357

Published: 2012

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV

Blood (2012) 120 (21): 913.

https://doi.org/10.1182/blood.V120.21.913.913

Published: 2012

Journal Articles

Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q)

Gudrun Göhring, Simone Feurstein, Winfried Hofmann, PhD, Arnold Ganser, Hans H. Kreipe, MD, Brigitte Schlegelberger

Blood (2012) 120 (21): 522.

https://doi.org/10.1182/blood.V120.21.522.522

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Blood (2011) 118 (21): 782.

https://doi.org/10.1182/blood.V118.21.782.782

Published: 2011

Journal Articles

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Jan Krönke, Lars Bullinger, Frank G. Rücker, Verena I. Gaidzik, MD, Michael WM Kühn, Karin Bezet, Veronica Teleanu, Peter Paschka, MD, Daniela Späth, Thomas Kindler, MD, Helmut R. Salih, MD, Jürgen Krauter, MD, Arnold Ganser, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner

Blood (2011) 118 (21): 237.

https://doi.org/10.1182/blood.V118.21.237.237

Published: 2011

Journal Articles

Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,

Kathrin Lange, Dipl. Biochem., Beate Kuhlmann, PhD, Andrea Schienke, Axel Schambach, MD PhD, Ute Modlich, DVM, PhD, Christopher Baum, MD, Brigitte Schlegelberger, M.D., Gudrun Göhring, MD

Blood (2011) 118 (21): 4001.

https://doi.org/10.1182/blood.V118.21.4001.4001

Published: 2011

Journal Articles

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Katharina Wagner, MD, Frederik Damm, MD, Michael A Morgan, PhD, Felicitas Thol, M.D., Haiyang Yun, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Michael Heuser, M.D., Arnold Ganser, MD, Jürgen Krauter, MD

Blood (2011) 118 (21): 3554.

https://doi.org/10.1182/blood.V118.21.3554.3554

Published: 2011

Journal Articles

Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia

Gudrun Göhring, MD, Caroline Fedder, Kathrin Lange, Dipl. Biochem., Andrea Schienke, Winfried Hofmann, PhD, Hans H. Kreipe, MD, Brigitte Schlegelberger, M.D.

Blood (2011) 118 (21): 1761.

https://doi.org/10.1182/blood.V118.21.1761.1761

Published: 2011

Journal Articles

Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome

Blood (2011) 118 (21): 165.

https://doi.org/10.1182/blood.V118.21.165.165

Published: 2011

Journal Articles

The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients

Felicitas Thol, M.D., Michael Heuser, M.D., Claudia Winschel, Frederik Damm, MD, Katharina Wagner, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Gesine Bug, Oliver G. Ottmann, MD, PhD, Wolf-Karsten Hofmann, MD, Jürgen Krauter, MD, Ph.D., Arnold Ganser, MD

Blood (2011) 118 (21): 1734.

https://doi.org/10.1182/blood.V118.21.1734.1734

Published: 2011

Journal Articles

Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Christian Koenecke, MD, Felicitas Thol, MD, Patrick Löffeld, Stefanie Buchholz, MD, Michael Stadler, MD, Gudrun Göhring, MD, Elke Dammann, Moritz Kleine, MD, Wiebke Brauns, Michael Hallensleben, MD, Jörg Schmidtke, MD, Brigitte Schlegelberger, M.D., Jürgen Krauter, Arnold Ganser, MD, Michael Heuser, M.D.

Blood (2011) 118 (21): 1709.

https://doi.org/10.1182/blood.V118.21.1709.1709

Published: 2011

Journal Articles

Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML

Armin Leitner, MD, Susanne Saussele, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gudrun Göhring, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Michael Lauseker, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Rüdiger Hehlmann, MD, The German CML-Study Group

Blood (2010) 116 (21): 355.

https://doi.org/10.1182/blood.V116.21.355.355

Published: 2010

NARROW

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7

Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV

Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q)

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia

Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome

The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients

Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only